Compare Summit Therapeutics Inc (SMMT) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Symbotic Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Symbotic Inc trades at $42.71 (market cap $5.19B). The key difference: Summit Therapeutics Inc is far larger — about 2× Symbotic Inc's market cap. Which is the better fit depends on your goals.
| SMMT | SYM | |
|---|---|---|
Market Cap | $10.48B | $5.19B |
Sector | Health | Technology |
52-Week High | $29.32 | $87.30 |
52-Week Low | $13.05 | $38.57 |
Enterprise Value | $9.90B | $3.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
SYM trades at $40.83, down 1.02% with bearish technical signals despite recent earnings beats. The company shows revenue growth potential with $2.25B in 2025 revenue and improving margins, though net income remains negative. Analyst consensus is bullish with a $57.50 price target, while technical indicators show oversold conditions with RSI at 29.43. Recent news highlights Symbotic's positioning in warehouse robotics and AI automation.
The stock presents a growth opportunity in the expanding warehouse automation market, supported by strong analyst buy ratings and improving financial trends. Key risks include continued negative profitability, high valuation multiples, and competitive pressures in the robotics sector. Near-term catalysts include Q2 2026 earnings and execution on the company's $1.1B projected net cash flow for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
